5402222025-01-012025-03-315402222025-03-315402222024-03-315402222024-04-012025-03-315402222025-01-012025-03-31in-capmkt:OtherExpenses1Member5402222024-04-012025-03-31in-capmkt:OtherExpenses1Member5402222025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15402222024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15402222025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2024-04-012025-03-312025-04-242025-04-10INRCroresQuarterlyFourth quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2025-04-2414:00:002025-04-2414:45:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated17203000000585700000177887000006263300000223100000134040000017770000005640000001104300000339320000014665300000312340000003123400000803400000-1870000078470000002338700000000-110000002327700000-2070000023070000002336700000-90000002316000000-9000000107850000024.344.33004.344.330001. The above consolidated financial results of Laurus Labs Limited including its subsidiaries Collectively known as the Group, and its associates and joint venture as mentioned in note 3 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on April 24, 2025. The results for the year ended March 31, 2025 has been audited and for the quarter ended March 31, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2025 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2025. <BR> 2. These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. <BR> 3. The consolidated financial results include the results of the following entities <BR> Please view table from results pdf <BR> 4. a The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited in India on December 01, 2022. LSCPL has not commenced its operations. <BR> b) During the quarter ended December 31, 2024, the Laurus Bio Private Limited has entered into definitive agreement with Eight Roads Ventures India Healthcare IV, L.P. and F Prime Capital Partners Life Sciences Fund VIII LP, Pursuant to this agreement Investors have together invested Rs. 120 Crores into Laurus Bio. <BR> c) Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited, Capital contribution have been made into KRKA interms of the aforesaid agreement during the quarter for 49 percent stake. The Company has accounted for the investment in KRKA as joint venture w.e.f. October 03, 2024. <BR> 5. The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. <BR> 6. During the year ended March 31, 2025, the Company allotted 286,633 equity shares of Rs. 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 7. The Board of Directors, at their meeting held on April 24, 2025 approved for the payment of interim dividend of Rs. 0.80 per equity share of Rs. 2 each. <BR> 8. During the quarter ended March 31, 2025, the Holding Company sold its land situated at MN Park, Hyderabad, Telangana at fair value to KRKA Pharma Private Limited and recognised the profit of Rs. 58.85 crores, which was classified as Other Income. <BR> 9. The figures for the current quarter and quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and March 31, 2024, respectively and published year to date figures up to third quarter ended December 31, 2024 and December 31, 2023, respectively, which are subject to limited review by the statutory auditors.2024-04-012025-03-31AuditedConsolidated5553960000075100000056290600000242855000001053600000-55930000071952000002160000000430090000013011800000514477000004842900000048429000001569000000-270200000129880000003544100000000393000003583400000-3650000035469000003583200000200000354670000020000010785000002436471000006.656.64006.656.64000Other Expenses3393200000Other Expenses1301180000036684600000458360000002463000000193200000000233260000000486600000281920000069400000321950000050032500000193654000000200716000009954000004467000009300000586000002158160000002376200000433232000000093355700000107850000043647100000447256000001299600000460252000006455800000000621900000707770000010609000003187000000347600000011933300000204750000002775000009307400000958490000034607000003352060000010112000002934000005720000000353972000000047330500000933557000000-828600000-404960000000-549600000266170000000-979900000000430090000000000-19200000015170000010230000000-570500000000-8420000047587000000-2099600000013754000005336000006016500000000001053500000009987000006410000000000000000000000000615000000-413900000-6817200000000000101700000050277000003157000000309300000431300000209220000001253200000392800000-40790000013900000-3940000001389400000995400000Remeasurement gains/(losses) on defined benefit plans-30100000Income tax relating to items that will not be reclassified to profit or loss in subsequent periods7900000Share in other comprehensive income of associates and joint venture, net oftax-100000-22300000Remeasurement gains/(losses) on defined benefit plans-18700000Income tax relating to items that will not be reclassified to profit or loss in subsequent periods5000000Share in other comprehensive income of associates and joint venture, net oftax-100000-1380000000Exchange differences on translating the financial statements of foreign operations16000001600000Exchange differences on translating the financial statements of foreign operations-22700000-2270000000-20700000-36500000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31